Literature DB >> 10345162

Economic evaluation of antibacterials in the treatment of acute sinusitis.

C Laurier1, J Lachaine, M Ducharme.   

Abstract

OBJECTIVE: The objective of this study was to compare costs, efficacy and cost efficacy of alternate oral antibacterial regimens for the ambulatory treatment of acute sinusitis. A public third-party perspective was adopted.
DESIGN: The analysis was based on a decision tree and considered the episode of care from the decision to initiate an antibacterial until the end of the first course of treatment or the end of a subsequent course of treatment when needed. Efficacy data were retrieved from published clinical trials. Direct medical costs included the costs of physician visits, diagnostic tests and medications.
SETTING: The study pertained to adults treated in a primary-care setting in the Canadian province of Québec.
INTERVENTIONS: The antibacterials studied were amoxicillin, amoxicillin/clavulanate, azithromycin, cefaclor, cefuroxime axetil and clarithromycin. MAIN OUTCOME MEASURES AND
RESULTS: The main outcome measured was the proportion of patients showing resolution or improvement of their symptoms. Initiating a treatment with amoxicillin was associated with similar efficacy and lower overall costs when compared with the other antibacterials. Low dosages of clarithromycin and azithromycin followed amoxicillin in terms of cost-efficacy ratio.
CONCLUSIONS: This study confirms the place of amoxicillin as a first choice agent for acute sinusitis, with low dose clarithromycin and azithromycin as second choices.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10345162     DOI: 10.2165/00019053-199915010-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  63 in total

Review 1.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

Review 2.  Diagnosis and management of sinusitis.

Authors:  K L Evans
Journal:  BMJ       Date:  1994-11-26

3.  Sulbactam/ampicillin in the treatment of otitis and sinusitis.

Authors:  G Nicoletti; A Speciale; F Caccamo; F Raso
Journal:  J Int Med Res       Date:  1991       Impact factor: 1.671

4.  [Efficacy and tolerability of cefixime in the treatment of otorhinolaryngeal infections in adults].

Authors:  R Peynègre; B Bossard; P Gehanno
Journal:  Presse Med       Date:  1989-10-11       Impact factor: 1.228

Review 5.  Acute and chronic sinusitis. How to ease symptoms and locate the cause.

Authors:  B J Ferguson
Journal:  Postgrad Med       Date:  1995-05       Impact factor: 3.840

6.  Clinical efficacy of ofloxacin in the treatment of otorhinolaryngological infections.

Authors:  S Baba
Journal:  Infection       Date:  1986       Impact factor: 3.553

7.  [Efficacy and tolerability of cefuroxime-axetil in infections of the upper respiratory tract. Comparative study with cefadroxil].

Authors:  G Dupuis; D Ebbo; A Evennou; M Pappo
Journal:  Rev Laryngol Otol Rhinol (Bord)       Date:  1989

8.  Acute bacterial sinusitis. Minocycline vs amoxicillin.

Authors:  K F Mattucci; W J Levin; M A Habib
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1986-01

9.  Treatment of acute maxillary sinusitis--comparing cefpodoxime proxetil with amoxicillin.

Authors:  C von Sydow; S Savolainen; A Söderqvist
Journal:  Scand J Infect Dis       Date:  1995

10.  Therapeutic efficacy and tolerability of brodimoprim in comparison with doxycycline in acute sinusitis in adults.

Authors:  J Arndt; D Riebenfeld; H Maier; H Weidauer
Journal:  J Chemother       Date:  1994-10       Impact factor: 1.714

View more
  2 in total

Review 1.  Formulations of antibiotics for children in primary care: effects on compliance and efficacy.

Authors:  Andres Ramgoolam; Russell Steele
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 2.  Acute rhinosinusitis : a pharmacoeconomic review of antibacterial use.

Authors:  Jean-Blaise Wasserfallen; Françoise Livio; Giorgio Zanetti
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.